| Attribute |
Value |
| 52 Week Change |
-0.80410445 |
| Address1 |
3 Lochside Way |
| All Time High |
160,000.0 |
| All Time Low |
0.948 |
| Ask |
1.38 |
| Ask Size |
2 |
| Average Daily Volume10 Day |
477,910 |
| Average Daily Volume3 Month |
119,918 |
| Average Volume |
119,918 |
| Average Volume10Days |
477,910 |
| Beta |
2.314 |
| Bid |
0.9288 |
| Bid Size |
2 |
| Book Value |
6.209551 |
| City |
Edinburgh |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United Kingdom |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
1.05 |
| Current Ratio |
4.729 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
1.065 |
| Day Low |
1.03 |
| Debt To Equity |
3.317 |
| Display Name |
NuCana |
| Dividend Yield |
0.0 |
| Earnings Timestamp End |
1,755,518,400 |
| Earnings Timestamp Start |
1,755,082,740 |
| Ebitda |
-14,400,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
0.993 |
| Enterprise Value |
-14,306,072 |
| Eps Forward |
-9.43 |
| Eps Trailing Twelve Months |
0.0 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
1.3544 |
| Fifty Day Average Change |
-0.3044001 |
| Fifty Day Average Change Percent |
-0.22474903 |
| Fifty Two Week Change Percent |
-80.410446 |
| Fifty Two Week High |
6.1 |
| Fifty Two Week High Change |
-5.05 |
| Fifty Two Week High Change Percent |
-0.8278689 |
| Fifty Two Week Low |
0.948 |
| Fifty Two Week Low Change |
0.10199994 |
| Fifty Two Week Low Change Percent |
0.10759487 |
| Fifty Two Week Range |
0.948 - 6.1 |
| Financial Currency |
GBP |
| First Trade Date Milliseconds |
1,506,605,400,000 |
| Float Shares |
4,309,196 |
| Forward Eps |
-9.43 |
| Forward P E |
-0.11134676 |
| Free Cashflow |
-6,370,000 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
10 |
| Fullday Change |
-0.01999998 |
| Fullday Change Percent |
-1.9047601 |
| Fullday Price |
1.05 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.000010000001 |
| Held Percent Institutions |
0.025969999 |
| Implied Shares Outstanding |
4,161,971 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,754,870,400 |
| Last Split Factor |
1:200 |
| Long Business Summary |
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom. |
| Long Name |
NuCana plc |
| Market |
us_market |
| Market Cap |
4,370,069 |
| Market State |
POST |
| Max Age |
86,400 |
| Message Board Id |
finmb_50918463 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-9,711,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
5,452,181 |
| Open |
1.05 |
| Operating Cashflow |
-5,117,000 |
| Operating Margins |
0.0 |
| Payout Ratio |
0.0 |
| Phone |
44 13 1357 1111 |
| Previous Close |
1.05 |
| Price Hint |
4 |
| Price To Book |
0.16909435 |
| Profit Margins |
0.0 |
| Quick Ratio |
4.557 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
0.0 |
| Regular Market Change Percent |
0.0 |
| Regular Market Day High |
1.065 |
| Regular Market Day Low |
1.03 |
| Regular Market Day Range |
1.03 - 1.065 |
| Regular Market Open |
1.05 |
| Regular Market Previous Close |
1.05 |
| Regular Market Price |
1.05 |
| Regular Market Time |
1,792,008,000 |
| Regular Market Volume |
38,043 |
| Return On Assets |
-0.43487 |
| Return On Equity |
-0.70258003 |
| Sand P52 Week Change |
0.17004645 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
4,161,971 |
| Shares Percent Shares Out |
0.024 |
| Shares Short |
99,936 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
158,689 |
| Short Name |
NuCana plc |
| Short Percent Of Float |
0.024 |
| Short Ratio |
0.53 |
| Source Interval |
15 |
| Symbol |
NCNA |
| Total Cash |
19,503,000 |
| Total Cash Per Share |
4.526 |
| Total Debt |
672,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
0.0 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
1.91345 |
| Two Hundred Day Average Change |
-0.86345005 |
| Two Hundred Day Average Change Percent |
-0.451253 |
| Type Disp |
Equity |
| Volume |
38,043 |
| Website |
https://www.nucana.com |
| Zip |
EH12 9DT |